BGI Group JSC (HNX:VC7)
Vietnam · Delayed Price · Currency is VND 10,300
-400 (-3.74%)
At close: Aug 1, 2025
Ligand Pharmaceuticals Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '19 Dec 31, 2019 | 2016 - 2020 |
| 363,701 | 293,915 | 373,424 | 325,139 | 124,564 | 127,826 | Upgrade | |
Revenue Growth (YoY) | -0.19% | -21.29% | 14.85% | 161.02% | -2.55% | -0.52% | Upgrade |
Cost of Revenue | 311,304 | 249,991 | 302,239 | 284,431 | 117,123 | 123,367 | Upgrade |
Gross Profit | 52,396 | 43,924 | 71,185 | 40,708 | 7,441 | 4,459 | Upgrade |
Selling, General & Admin | 27,724 | 23,404 | 23,181 | 19,501 | 17,642 | 21,889 | Upgrade |
Operating Expenses | 27,724 | 23,404 | 23,181 | 19,501 | 17,642 | 21,889 | Upgrade |
Operating Income | 24,672 | 20,521 | 48,004 | 21,207 | -10,201 | -17,430 | Upgrade |
Interest Expense | -9,568 | -8,576 | -10,199 | -10,842 | -6,026 | -1,911 | Upgrade |
Interest & Investment Income | 957.88 | 831.17 | 291.95 | 2,438 | 1,530 | 861.25 | Upgrade |
Earnings From Equity Investments | 5,228 | 5,863 | 10,694 | 419.06 | 187.99 | - | Upgrade |
Other Non Operating Income (Expenses) | -2,121 | -171.05 | -427.2 | -254.75 | 27,358 | 38,564 | Upgrade |
Pretax Income | 19,169 | 18,468 | 48,363 | 12,968 | 12,849 | 20,085 | Upgrade |
Income Tax Expense | 2,542 | 3,372 | 5,896 | -20.94 | 4,441 | 7,971 | Upgrade |
Earnings From Continuing Operations | 16,627 | 15,096 | 42,467 | 12,989 | 8,408 | 12,113 | Upgrade |
Minority Interest in Earnings | -102.94 | -798.43 | -1,859 | -441.98 | 309.05 | - | Upgrade |
Net Income | 16,524 | 14,298 | 40,608 | 12,547 | 8,717 | 12,113 | Upgrade |
Net Income to Common | 16,524 | 14,298 | 40,608 | 12,547 | 8,717 | 12,113 | Upgrade |
Net Income Growth | -58.06% | -64.79% | 223.65% | 43.94% | -28.04% | -39.70% | Upgrade |
Shares Outstanding (Basic) | 154 | 154 | 50 | 48 | 41 | 24 | Upgrade |
Shares Outstanding (Diluted) | 154 | 154 | 50 | 48 | 41 | 24 | Upgrade |
Shares Change (YoY) | 146.21% | 204.77% | 4.93% | 17.47% | 70.21% | 100.12% | Upgrade |
EPS (Basic) | 107.48 | 93.00 | 805.00 | 261.00 | 213.00 | 503.81 | Upgrade |
EPS (Diluted) | 107.48 | 93.00 | 805.00 | 261.00 | 213.00 | 503.81 | Upgrade |
EPS Growth | -82.96% | -88.45% | 208.43% | 22.54% | -57.72% | -69.87% | Upgrade |
Free Cash Flow | -99,030 | -49,560 | -428,497 | -92,008 | -169,603 | -103,014 | Upgrade |
Free Cash Flow Per Share | -644.13 | -322.36 | -8494.41 | -1913.95 | -4144.41 | -4284.57 | Upgrade |
Gross Margin | 14.41% | 14.94% | 19.06% | 12.52% | 5.97% | 3.49% | Upgrade |
Operating Margin | 6.78% | 6.98% | 12.86% | 6.52% | -8.19% | -13.64% | Upgrade |
Profit Margin | 4.54% | 4.87% | 10.87% | 3.86% | 7.00% | 9.48% | Upgrade |
Free Cash Flow Margin | -27.23% | -16.86% | -114.75% | -28.30% | -136.16% | -80.59% | Upgrade |
EBITDA | 34,388 | 32,119 | 58,398 | 28,710 | -3,676 | -12,924 | Upgrade |
EBITDA Margin | 9.46% | 10.93% | 15.64% | 8.83% | -2.95% | -10.11% | Upgrade |
D&A For EBITDA | 9,716 | 11,599 | 10,394 | 7,502 | 6,526 | 4,507 | Upgrade |
EBIT | 24,672 | 20,521 | 48,004 | 21,207 | -10,201 | -17,430 | Upgrade |
EBIT Margin | 6.78% | 6.98% | 12.86% | 6.52% | -8.19% | -13.64% | Upgrade |
Effective Tax Rate | 13.26% | 18.26% | 12.19% | - | 34.56% | 39.69% | Upgrade |
Revenue as Reported | 363,701 | 293,915 | 373,424 | 325,139 | 124,564 | 127,826 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.